Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leela Barham

Latest From Leela Barham

Lords Call For UK Government To Secure A ‘Growth’ Pricing Deal With Pharma

The House of Lords held a debate on the UK’s statutory drug pricing scheme as a way of drawing attention to the need for a voluntary price deal that can revive the international competitiveness of the life science industry.

Europe United Kingdom

What Role Is There for Patients In Managed Access Deals?

Market access deals can make or break routine access to new treatments. So what happens when patient-centricity and deal-making meet? Leela Barham looks at the experience in England.

Market Access Pricing Strategies

The People Who Will Shape The UK’s New Drug Pricing Scheme

With talks on the next UK voluntary pricing scheme now well under way, the Pink Sheet looks at the industry and government negotiators who will be thrashing out the details in the coming months.

Europe United Kingdom

UK Parliamentarians Call For A New, Internationally Competitive Pricing System

Much-needed investment could be lost if the “uncompetitive” sales rebate rate is not reduced as part of talks on a new UK drug pricing scheme, some parliamentarians are warning.

Europe United Kingdom

Patient Groups Want More Say In Talks On New UK Pricing Deal

The Association of the British Pharmaceutical Industry has welcomed calls from three patient group umbrella organizations to be more involved as the UK government negotiates with the ABPI on a successor to the 2019 voluntary pricing scheme.

Europe United Kingdom

Legal Challenge Could Put UK Drug Pricing Deal At Risk

The body representing generics and biosimilars companies in the UK is seeking a seat at the table as negotiations on a new voluntary price scheme get under way.

Europe United Kingdom
See All
UsernamePublicRestriction

Register